47 results on '"Allez, Matthieu"'
Search Results
2. Impact de la COVID-19 sur l'initiation des prescriptions des biothérapies dans les maladies inflammatoires chroniques.
- Author
-
Richette, Pascal, Allez, Matthieu, Descamps, Vincent, Perray, Lucas, Pilet, Simon, Latourte, Augustin, and Maravic, Milka
- Published
- 2022
- Full Text
- View/download PDF
3. Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial.
- Author
-
Hawkey, Christopher J., Allez, Matthieu, Clark, Miranda M., Labopin, Myriam, Lindsay, James O., Ricart, Elena, Rogler, Gerhard, Rovira, Montserrat, Satsangi, Jack, Danese, Silvio, Russell, Nigel, Gribben, John, Johnson, Peter, Larghero, Jerome, Thieblemont, Catherine, Ardizzone, Sandro, Dierickx, Daan, Ibatici, Adalberto, Littlewood, Timothy, and Onida, Francesco
- Subjects
- *
CROHN'S disease , *AUTOGRAFTS , *BIOTHERAPY , *HEMATOPOIETIC stem cell transplantation , *IMMUNOSUPPRESSION , *QUALITY of life , *RESEARCH funding , *STATISTICAL sampling , *TIME , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *DISEASE remission , *THERAPEUTICS - Abstract
Importance: Case reports and series suggest hematopoietic stem cell transplantation (HSCT) may benefit some patients with Crohn disease.Objective: To evaluate the effect of autologous HSCT on refractory Crohn disease.Design, Setting, and Participants: Parallel-group randomized clinical trial conducted in 11 European transplant units from July 2007 to September 2011, with follow-up through March 2013. Patients were aged 18 to 50 years with impaired quality of life from refractory Crohn disease not amenable to surgery despite treatment with 3 or more immunosuppressive or biologic agents and corticosteroids.Interventions: All patients underwent stem cell mobilization before 1:1 randomization to immunoablation and HSCT (n = 23) or control treatment (HSCT deferred for 1 year [n = 22]). All were given standard Crohn disease treatment as needed.Main Outcomes and Measures: Sustained disease remission at 1 year, a composite primary end point comprising clinical remission (Crohn Disease Activity Index (CDAI) <150 [range, 0-600]), no use of corticosteroids or immunosuppressive or biologic drugs for at least the last 3 months, and no endoscopic or radiological evidence of active (erosive) disease anywhere in the gastrointestinal (GI) tract. Secondary outcomes were individual components of the primary composite outcome and other measures of disease activity, laboratory results, quality of life and functional status, and GI tract imaging.Results: Twenty-three patients underwent HSCT and 22 received standard Crohn disease treatment (controls). Sustained disease remission was achieved in 2 patients undergoing HSCT (8.7%) vs 1 control patient (4.5%) (absolute difference, 4.2% [95% CI, -14.2% to 22.6%]; P = .60). Fourteen patients undergoing HSCT (61%) vs 5 control patients (23%) had discontinued immunosuppressive or biologic agents or corticosteroids for at least 3 months (difference, 38.1% [95% CI, 9.3% to 59.3%]; P = .01). Ten vs 2 patients had a CDAI less than 150 (remission) at the final evaluation, 8 (34.8%) vs 2 (9.1%) for 3 or more months (difference, 25.7% [95% CI, 1.1% to 47.1%]; P = .052). Eight (34.8%) vs 2 (9.1%) patients were adjudicated free of active disease on endoscopy and radiology at final assessment (difference, 25.7% [95% CI, 1.1% to 47.1%]; P = .054). There were 76 serious adverse events in patients undergoing HSCT vs 38 in controls. One patient undergoing HSCT died.Conclusions and Relevance: Among adult patients with refractory Crohn disease not amenable to surgery who had impaired quality of life, HSCT, compared with conventional therapy, did not result in a statistically significant improvement in sustained disease remission at 1 year and was associated with significant toxicity. These findings do not support the widespread use of HSCT for patients with refractory Crohn disease.Trial Registration: clinicaltrials.gov Identifier: NCT00297193. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
4. COVID‐19–Related IgA Vasculitis.
- Author
-
Allez, Matthieu, Denis, Blandine, Bouaziz, Jean‐David, Battistella, Maxime, Zagdanski, Anne‐Marie, Bayart, Jules, Lazaridou, Ingrid, Gatey, Caroline, Pillebout, Evangeline, Chaix Baudier, Marie‐Laure, Delaugerre, Constance, Molina, Jean‐Michel, and Le Goff, Jérôme
- Subjects
- *
BIOPSY , *CROHN'S disease , *IMMUNOGLOBULINS , *COVID-19 testing , *POLYMERASE chain reaction , *VASCULITIS , *TREATMENT effectiveness , *ENOXAPARIN , *METHYLPREDNISOLONE , *COVID-19 , *SYMPTOMS - Abstract
The article presents a case study related to 24-year-old man with Crohn's disease (CD) was admitted to our hospital with a 9-day history of skin rash, severe asymmetric arthralgia, periarticular swelling, and abdominal pain. Topics include the moderately severe, diffuse abdominal pain, and he had no intestinal bleeding, and the physical examination revealed palpable purpura on the legs and arms, swelling of the left hand, and pain on palpation of several joints without signs of arthritis.
- Published
- 2020
- Full Text
- View/download PDF
5. Impact of COVID-19 on initiation of biologic therapy prescriptions for chronic inflammatory diseases.
- Author
-
Richette, Pascal, Allez, Matthieu, Descamps, Vincent, Perray, Lucas, Pilet, Simon, Latourte, Augustin, and Maravic, Milka
- Subjects
- *
BIOTHERAPY , *CHRONIC diseases , *COVID-19 , *MEDICAL prescriptions - Published
- 2022
- Full Text
- View/download PDF
6. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
- Author
-
Allez, Matthieu, Karmiris, Konstantinos, Louis, Edouard, Van Assche, Gert, Ben-Horin, Shomron, Klein, Amir, Van der Woude, Janneke, Baert, Filip, Eliakim, Rami, Katsanos, Konstantinos, Brynskov, Jørn, Steinwurz, Flavio, Danese, Silvio, Vermeire, Severine, Teillaud, Jean-Luc, Lémann, Marc, and Chowers, Yehuda
- Subjects
- *
EXTRACORPOREAL carbon dioxide removal , *TUMOR necrosis factors , *INFLAMMATORY bowel disease treatment , *PHARMACOLOGY , *MONOCLONAL antibodies , *INFLIXIMAB , *ENZYME-linked immunosorbent assay , *TUMOR treatment - Abstract
Abstract: The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). The overall objective was to better understand and explore primary non response and loss of response to anti-TNF agents in IBD. The outcome of this workshop is presented into two parts. This first section addresses definitions, frequency and pharmacological aspects of anti-TNF therapy failure, including pharmacokinetics of anti-TNF monoclonal antibodies and immune and non-immune mediated clearance of anti-TNF mAbs. The second section concerns the biological roles of TNF and TNF antagonists, including mechanisms of action of anti-TNF agents, and discuss hypothesis regarding their failures and phenomenon of paradoxical inflammation, including the potential role of TNF independent inflammatory pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
7. Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-γ.
- Author
-
Dotan, Iris, Allez, Matthieu, Nakazawa, Atsushi, Brimnes, Jens, Schulder-Katz, Micoll, and Mayer, Lloyd
- Subjects
- *
EPITHELIAL cells , *INTERFERONS , *CELL proliferation , *T cells , *CROHN'S disease , *ULCERATIVE colitis , *CYTOKINES - Abstract
Previous studies have suggested that intestinal epithelial cells (IECs) have the capacity to function as nonprofessional antigen presenting cells that in the normal state preferentially activate CD8+ T cells. However, under pathological conditions, such as those found in inflammatory bowel disease (IBD), persistent activation of CD4+ T cells is seen. The aim of this study was to determine whether the IBD IECs contribute to CD4+ T cell activation. Freshly isolated human IECs were obtained from surgical specimens of patients with or without IBD and cocultured with autologous or allogeneic peripheral blood T lymphocytes. Cocultures of normal T cells and IECs derived from IBD patients resulted in the preferential activation of CD4+ T cell proliferation that was associated with significant 1FN-γ, but not IL-2, secretion. Cytokine secretion and CD4+ T cell proliferation was inhibited by pretreatment of the IBD IECs with the anti-DR MAb L243. In contrast, normal IECs stimulated the proliferation and cytokine secretion by CD4+ T cells to a significantly lesser degree than IBD IECs. Furthermore, blockade of human leukocyte antigen-DR had a lesser effect in the normal IEC-CD4+ T cell cocultures. We conclude that IECs can contribute to the ongoing CD4+ T cell activation seen in IBD. We suggest that the apparent differences between the secreted levels of IFN-γ indicate that it may play a dual role in intestinal homeostasis, in which low levels contribute to physiological inflammation whereas higher levels are associated with an uncontrolled inflammatory state. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
8. Immunomodulatory Roles of the Carcinoembryonic Antigen Family of Glycoproteins.
- Author
-
SHAO, LING, ALLEZ, MATTHIEU, PARK, MEE‐SOOK, and MAYER, LLOYD
- Subjects
- *
CARCINOEMBRYONIC antigen , *GLYCOPROTEINS , *IMMUNE system , *CELL adhesion , *CELL communication , *T cells - Abstract
One of the most remarkable aspects of the immune system is its ability to fashion an immune response most appropriate to the activating stimulus. Although the immune system possesses a number of adaptations to accomplish this, an important theme is local immune regulation by site-specific expression of receptors and ligands. One family of molecules that is gaining attention as modulators of the immune system is the carcinoembryonic antigen cell-adhesion molecule family (CEACAM). Functionally, the carcinoembryonic antigen family can mediate cell-cell contact, host-pathogen interactions, and immune regulation. For example, biliary glycoprotein (CEACAM1) can have direct activity on T cells, leading to the inhibition of helper or cytotoxic T cell function. The expression of carcinoembryonic antigen (CEACAM5) on intestinal epithelial cells is involved in the activation of populations of regulatory CD8+ T cells, while a distinct subset of regulatory CD8+ T cells is activated by nonspecific cross-reacting antigen (CEACAM6) on placental trophoblasts. Interestingly, the function and phenotype of these cells depend upon the specific member of the carcinoembryonic antigen family expressed, as well as the antigen-presenting molecule with which it associates. Thus, these glycoproteins comprise a family of molecules whose functions can depend on their nature and context. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
9. Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy1 <FN ID="FN1"><NO>1</NO>Some of these data have been presented in abstract form (Gastroenterology 1996;110:A853).</FN>
- Author
-
Allez, Matthieu, Lemann, Marc, Bonnet, Joëlle, Cattan, Pierre, Jian, Raymond, and Modigliani, Robert
- Subjects
- *
CROHN'S disease , *COLECTOMY - Abstract
OBJECTIVE:Prediction of the clinical course of Crohn’s disease (CD) is difficult in the long term. Our aim was to determine whether the presence of severe endoscopic lesions (SELs) may predict a higher risk of colectomy and penetrating complications.METHODS:All patients at our institution with active ileocolonic CD who had colonoscopies between 1990 and 1996 were included in the study. SELs were defined as extensive and deep ulcerations covering more than 10% of the mucosal area of at least one segment of the colon.RESULTS:Among the 102 patients included, 53 had SELs at index colonoscopy. During the follow-up (median = 52 months), 37 patients underwent colonic resection. Probabilities of colectomy at 1, 3, and 8 yr were 20%, 26%, and 42%. Risk of colectomy was independently affected by the presence of SELs at index colonoscopy (relative risk [RR] = 5.43, 95% CI = 2.64–11.18), a Crohn’s Disease Activity Index level greater than 288 (RR = 2.21, 95% CI = 1.09–4.47), and the absence of immunosuppressive therapy during the follow-up (RR = 2.44, 95% CI = 1.20–5.00). Probabilities of colectomy were, respectively, 31% and 6% at 1 yr, 42% and 8% at 3 yr, and 62% and 18% at 8 yr in patients with and without SELs. We performed a second analysis excluding the 14 patients operated on within the 3 months after the index colonoscopy: presence of SELs remained the only significant factor predictive of colectomy (RR = 6.72, 95% CI = 2.26–20.03). All six patients with penetrating complications during the follow-up had SELs at index colonoscopy.CONCLUSIONS:Patients with CD exhibiting deep and extensive ulcerations at colonoscopy have a more aggressive clinical course with an increased rate of penetrating complications and surgery. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
10. Systematic review: Patient‐related, microbial, surgical, and histopathological risk factors for endoscopic post‐operative recurrence in patients with Crohn's disease.
- Author
-
Bak, Michiel T. J., Demers, Karlijn, Hammoudi, Nassim, Allez, Matthieu, Silverberg, Mark S., Fuhler, Gwenny M., Parikh, Kaushal, Pierik, Marieke J., Stassen, Laurents P. S., Woude, C. Janneke, Doukas, Michail, Ruler, Oddeke, and Vries, Annemarie C.
- Abstract
Summary Background Aims Methods Results Conclusion Risk stratification for endoscopic post‐operative recurrence (ePOR) in Crohn's disease (CD) is required to identify patients who would benefit most from initiation of prophylactic medication and intensive monitoring of recurrence.To assess the current evidence on patient‐related, microbial, surgical and histopathological risk factors for ePOR in patients with CD after ileocolic (re‐)resection.Multiple online databases (Embase, MEDLINE, Web of Science and Cochrane Library) were searched up to March 2024. Studies with reported associations of patient‐related, microbial, surgical and/or histopathological factors for ePOR (i.e., Rutgeerts’ score ≥i2 or modified Rutgeerts’ score ≥i2a) were included. The risk of bias was assessed with the Newcastle‐Ottawa Scale for observational cohort studies and case‐control studies.In total, 47 studies were included (four RCTs, 29 cohort studies, 12 case–control studies, one cross‐sectional study and one individual participant data meta‐analysis) including 6006 patients (median sample size 87 patients [interquartile range 46–170]). Risk of bias assessment revealed a poor quality in 41% of the studies. An association was reported in multiple studies of ePOR with active smoking at and post‐surgery, male sex and prior bowel resection. A heterogeneous association with ePOR was reported for other risk factors included in the current guidelines (penetrating disease, perianal disease, younger age, extensive small bowel disease and presence of granulomas in the resection specimen or myenteric plexitis in the resection margin), and other patient‐related, microbial, surgical and histopathological factors.Risk factors for ePOR in international guidelines are not consistently reported as risk factors in current literature except for active smoking and prior bowel resection. To develop evidence‐based, personalised strategies, large prospective studies are warranted to identify risk factors for ePOR. Validation studies of promising (bio)markers are also required. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative.
- Author
-
Hammoudi, Nassim, Hassid, Déborah, Bonnet, Joëlle, Tran Minh, My-Linh, Baudry, Clotilde, Vauthier, Anne, Chedouba, Leila, Houzé, Pascal, Lourenco, Nelson, Aparicio, Thomas, Gornet, Jean-Marc, and Allez, Matthieu
- Subjects
- *
INFLAMMATORY bowel diseases , *ALLERGY desensitization , *CROHN'S disease , *INFLIXIMAB , *INTENSIVE care units , *MEDICAL protocols - Abstract
Hypersensitivity reactions (HSR) to the administration of infliximab (IFX) in Inflammatory Bowel Diseases (IBD) patients are not rare and usually lead to drug discontinuation. We report data on safety and effectiveness of desensitization to IFX in patients with previous HSR. We conducted a retrospective monocentric observational study. Patients for whom a desensitization protocol to IFX was realized after a previous HSR were included. Anti-drug antibodies (ADA) and IFX trough levels at both inclusion and six months after desensitization were collected. Clinical outcomes, including recurrence of HSR were evaluated. From 2005 to 2020, 27 patients (Crohn's Disease: 26 (96%) were included). Desensitization after HSR was performed after a median time of 10.4 months (2.9-33.1). Nineteen (70%) patients received immunosuppressants at time of desensitization. Eight (30%) patients presented HSR at first (n = 2), second (n = 4) or third (n = 2) IFX perfusion after desensitization. None led to intensive care unit transfer or death. Thirteen (48%) had clinical response at 6 months and 8 (29%) were still under IFX treatment two years after desensitization. IFX trough levels and ADA were available for 14 patients at time of desensitization. Most patients (12 out of 14) had ADA at a high level. At 6 months, among the 7 patients with long term response to IFX, 4 presented a decrease of ADA titers and 2 had a significant trough level of IFX. IFX desensitization in patients with IBD is a safe therapeutic alternative and represents a potential option for patients refractory to multiple biologics. What is already known? Hypersensitivity reactions to the administration of infliximab is frequent. Occurrence of hypersensitivity reaction, either immediate or delayed, usually leads to permanent drug discontinuation. What is new here? Infliximab desensitization is well tolerated with no hypersensitivity reaction recurrence in 70% of patients. Clinical success at 6 months was of 48% and around a third of patients remained under infliximab therapy two years after desensitization. Antidrug antibodies decreased and infliximab trough levels increased in these patients showing the impact of desensitization on immunogenicity. How can this study help patient care? Infliximab desensitization represents a potential option for patients refractory to multiple biologics who presented hypersensitivity reaction to the drug. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Editorial: predicting recurrence of Crohn's disease after surgical resection—Close to a crystal ball. Authors' reply.
- Author
-
Allez, Matthieu, Auzolle, Claire, Le Bourhis, Lionel, and Seksik, Philippe
- Subjects
- *
CROHN'S disease , *ENDOSCOPY , *INVESTIGATIONAL therapies , *HUMAN microbiota - Abstract
Linked Content This article is linked to Auzolle et al and Allez and Auzolle papers. To view these articles visit https://doi.org/10.1111/apt.14944 and https://doi.org/10.1111/apt.14978. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Response to Hanzel.
- Author
-
Hammoudi, Nassim and Allez, Matthieu
- Subjects
- *
TISSUE wounds , *COLONOSCOPY , *SURGICAL anastomosis - Published
- 2021
- Full Text
- View/download PDF
14. Serious immune‐related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series.
- Author
-
Bresteau, Clément, Bonnet, Pauline, Robert, Caroline, Mussini, Charlotte, Saiag, Philippe, Buecher, Bruno, Lebbe, Celeste, Allez, Matthieu, Benamouzig, Robert, Hagège, Hervé, Bécheur, Hakim, Meyer, Antoine, and Carbonnel, Franck
- Subjects
- *
IMMUNE checkpoint inhibitors , *DRUG side effects , *DISEASE remission , *PNEUMOMEDIASTINUM - Abstract
Background: Immune checkpoint inhibitors (ICI) improve the prognosis of many cancers but cause immune‐related adverse events (IrAEs). Limited data are available on upper gastrointestinal (UGI) IrAEs. We describe the clinical characteristics, prognosis, and efficacy of medical therapy in patients with UGI IrAEs. Methods: This is a retrospective, multicenter cohort study of patients with UGI symptoms and moderate to severe endoscopic UGI lesions, occurring after ICI. Efficacy of induction medical therapy and at the most recent follow‐up was assessed. Results: Forty patients were included; of these, 34 (85%) received anti‐PD(L)1, either alone (n = 24) or combined with anti CTLA‐4 (n = 10). Eighteen patients (45%) had concomitant enterocolitis. All patients had severe endoscopic lesions (erosions, ulcerations, hemorrhage, or necrotic lesions). Three patients who received an inefficient initial medical treatment had a complicated course: One patient died of enterocolitis, one had a pneumomediastinum, and one developed an ulcerated stricture of the pylorus. Thirty‐five patients (88%) were treated with corticosteroids; 28 patients (80%) responded, and 20 (57%) reached clinical remission. Eight patients were treated with infliximab, and six responded (75%). After a median follow‐up of 11 months, 36 patients (90%) were in corticosteroid‐free clinical remission for their UGI symptoms. Endoscopic lesions persisted in 68% of patients. Conclusions: ICI cause severe UGI IrAEs, which are associated with enterocolitis in approximately half of the patients. Most patients with UGI IrAEs respond to corticosteroids or infliximab. These data support the recommendation to treat these patients without delay and in the same way as those with enterocolitis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Long‐term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids.
- Author
-
Salameh, Robert, Kirchgesner, Julien, Allez, Matthieu, Carbonnel, Franck, Meyer, Antoine, Gornet, Jean‐Marc, Beaugerie, Laurent, and Amiot, Aurelien
- Subjects
- *
ULCERATIVE colitis , *TUMOR necrosis factors , *BIOTHERAPY , *STEROIDS , *INFLAMMATORY bowel diseases , *MULTIVARIATE analysis - Abstract
Summary: Background: The long‐term outcome of patients with acute severe ulcerative colitis (ASUC) responding to intravenous steroids (IVS) has been poorly reported. Aims: To assess relapse‐free survival in patients with ASUC responding to IVS. Methods: Between January 2006 and December 2017, 142 consecutive patients with ASUC (according to modified Truelove‐and‐Witts criteria) responding to IVS were included in this multicentre retrospective study. Relapse was defined by a partial Mayo Clinic score >4 and/or the need for another maintenance therapy. Results: Among the 142 included patients (100 naïve of immunomodulator and/or biological agent) hospitalised for ASUC, 59 (41.5%) were treated at discharge with 5‐aminosalicylic acid, 60 (42%) with immunomodulators, 18 (13%) with anti‐tumour necrosis factor (TNF) agents and 5 (3.5%) with vedolizumab. After a median follow‐up of 4.8 (2.6‐7.3) years, 90 (63.4%) had relapsed and 12 (8.5%) had required colectomy. The probabilities of relapse‐free survival were 58%, 48% and 40% at 1, 2 and 5 years respectively. The multivariate analysis demonstrated that patients with <6 liquid stools per day at day 3 (hazard ratio 0.56, 95%CI [0.34‐0.91]), a partial Mayo Clinic score <2 at day 5 (0.41 [0.21‐0.80]) and anti‐TNF maintenance therapy (0.37 [0.16‐0.87]) were less likely to relapse. The probabilities of colectomy‐free survival were 96%, 95% and 91% at 1, 2 and 5 years respectively. Conclusion: Despite a high relapse rate, patients with ASUC responding to IVS had a low rate of colectomy after 5 years of follow‐up. Early response to IVS and maintenance therapy with biological agents were associated with a lower rate of relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. The multiple effects of tumour necrosis factor inhibitors on immune cells: new insights on inhibition of activation and cycling.
- Author
-
Allez, Matthieu
- Subjects
- *
TUMOR necrosis factors , *INFLAMMATORY bowel diseases , *IMMUNOSUPPRESSIVE agents , *T cells , *MONOCLONAL antibodies , *APOPTOSIS - Abstract
The author discusses the impact of the tumour necrosis factor on immune cells with respect to inducing the T-cell apoptosis and the inhibition of the T-cell function. The treatment of the therapeutic arsenal of the inflammatory bowel diseases can be achieved from the reaction of the immunosuppressants with the monoclonal antibodies of the anti-tumour necrosis factor. Information on the improvement of treatment efficiency through the use of immunosuppressants is also presented.
- Published
- 2012
- Full Text
- View/download PDF
17. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.
- Author
-
Meyer, Antoine, Fumery, Mathurin, Peyrin-Biroulet, Laurent, Filippi, Jérôme, Altwegg, Romain, Bouhnik, Yoram, Serrero, Melanie, Laharie, David, Roblin, Xavier, Nachury, Maria, Abitbol, Vered, Cadiot, Guillaume, Nancey, Stephane, Allez, Matthieu, Gilletta, Cyrielle, Vuitton, Lucine, Savoye, Guillaume, Nahon, Stephane, Bourrier, Anne, and Buisson, Anthony
- Subjects
- *
ULCERATIVE colitis , *VEDOLIZUMAB , *DISEASE remission , *COHORT analysis , *COLECTOMY - Abstract
There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails. We retrieved the full datasets of two observational, multicentre, retrospective studies of patients with UC for whom anti-TNF therapy failed and the patients were then treated with either vedolizumab or ustekinumab. The outcomes included steroid-free clinical remission, clinical remission, treatment persistence, colectomy, hospitalization, and serious and infectious adverse events. Propensity scores weighted comparison was applied. In total, 121 patients were included in the vedolizumab group and 97 were included in the ustekinumab group. At week 14 and week 52, in the weighted cohort, no difference was found between vedolizumab and ustekinumab for steroid-free clinical remission (OR = 0.55 [0.21–1.41], p =.21 and 0.94 [0.40–2.22], p =.89, respectively). There was no difference between vedolizumab and ustekinumab for secondary outcomes such as clinical remission, hospitalization, UC-related surgery, treatment persistence and serious and infectious adverse events. In patients with UC for whom anti-TNF therapy failed, no difference was found between vedolizumab and ustekinumab after propensity scores weighted comparison. Further studies are required to determine predictive factors of the efficacy of both biological agents. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. High Risk of Infectious Disease Caused by Salmonellae and Mycobacteria Infections in Patients with Crohn Disease Treated with Anti--Interleukin-12 Antibody.
- Author
-
Fieschi, Claire, Allez, Matthieu, and Casanova, Jean-Laurent
- Subjects
- *
LETTERS to the editor , *CROHN'S disease - Abstract
Presents a letter to the editor about high risk of infectious disease caused by Salmonellae and mycobacteria infections in patients with Crohn disease treated with anti-interleukin-12 antibody.
- Published
- 2005
- Full Text
- View/download PDF
19. Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID.
- Author
-
Boschetti, Gilles, Nachury, Maria, Laharie, David, Roblin, Xavier, Gilletta, Cyrielle, Aubourg, Alexandre, Bourreille, Arnaud, Zallot, Camille, Hebuterne, Xavier, Buisson, Anthony, Grimaud, Jean-Charles, Bouhnik, Yoram, Allez, Matthieu, Altwegg, Romain, Viennot, Stéphanie, Vuitton, Lucine, Carbonnel, Franck, Paul, Stéphane, Desseaux, Kristell, and Lambert, Jérome
- Subjects
- *
CROHN'S disease , *INFLIXIMAB , *DISEASE remission , *PREMEDICATION - Abstract
INTRODUCTION: The objective of this study was to describe the efficacy and safety of infliximab (IFX) reintroduction in Crohn's disease (CD) after stopping for loss of response or intolerance. METHODS: We conducted a prospective multicenter observational cohort study including adult patients with clinically (CD Activity Index >150) and objectively active luminal CD in whom IFX was reintroduced after at least 6 months of discontinuation. The reasons for the initial discontinuation could be a secondary loss of response or IFX intolerance. The reintroduction schedule included 3 IFX infusions at weeks 0, 4, and 8, after a systematic premedication. The primary end point was the efficacy of IFX retreatment at week 26 defined by a CD Activity Index of <150 in the absence of IFX discontinuation or use of corticosteroids, surgery, or other biologic. RESULTS: At week 26, 24 patients (35%) among the 69 analyzed reached the primary end point. No significant difference was observed between rates of clinical remission at week 26 in patients with prior LOR (n = 48) and those with IFX intolerance (n = 21) (35% and 33%, P = 0.87, respectively). Thirty-two acute infusion reactions were recorded in 27 patients, leading to withdrawal of IFX in 20 patients. No pharmacokinetic characteristic at baseline but detection of positive anti-drug antibodies at week 4 was predictive of IFX failure or infusion reaction at week 26. DISCUSSION: In this first prospective cohort study, IFX retreatment was safe and effective in one-third of the patients with CD, regardless the reason of prior discontinuation. Early detection of anti-drug antibodies can predict subsequent IFX reintroduction failure and infusion reactions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Gastrointestinal cancers in inflammatory bowel disease: An update with emphasis on imaging findings.
- Author
-
Barral, Matthias, Dohan, Anthony, Allez, Matthieu, Boudiaf, Mourad, Camus, Marine, Laurent, Valérie, Hoeffel, Christine, and Soyer, Philippe
- Subjects
- *
GASTROINTESTINAL cancer , *INFLAMMATORY bowel diseases , *COLON cancer risk factors , *MICROSATELLITE repeats , *CANCER treatment , *GENE therapy , *CANCER tomography - Abstract
Inflammatory bowel diseases (IBD) are associated with an increased risk of gastrointestinal cancers depending on the specific type of IBD, the extent of the disease and its location. Patients with IBD and extensive colonic involvement are at increased risk of colorectal cancer whereas patients with Crohn disease have an increased risk for small-bowel and anal carcinoma. These cancers preferentially develop on sites of longstanding inflammation. In regards to colon cancer, several key pathogenic events are involved, including chromosomal instability, microsatellite instability and hypermethylation. The risk for colon cancer in IBD patients correlates with longer disease duration, presence of sclerosing cholangitis, pancolitis, family history of colorectal cancer, early onset of the disease and severity of bowel inflammation. Identification of increased colorectal cancer risk in individual IBD patients has led to formal surveillance guidelines. Conversely, although an increased risk for other types of cancer has been well identified, no specific formal screening recommendations exist. Consequently, the role of the radiologist is crucial to alert the referring gastroenterologist when a patient with IBD presents with unusual imaging findings at either computed tomography (CT) or magnetic resonance (MR) imaging. This review provides an update on demographics, molecular, clinical and histopathological features of gastrointestinal cancers in IBD patients including colorectal carcinoma, small bowel adenocarcinoma, neuroendocrine tumors and anal carcinoma, along with a special emphasis on the current role of CT and MR imaging. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
21. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
- Author
-
Sands, Bruce E, Irving, Peter M, Hoops, Timothy, Izanec, James L, Gao, Long-Long, Gasink, Christopher, Greenspan, Andrew, Allez, Matthieu, Danese, Silvio, Hanauer, Stephen B, Jairath, Vipul, Kuehbacher, Tanja, Lewis, James D, Loftus, Edward V, Mihaly, Emese, Panaccione, Remo, Scherl, Ellen, Shchukina, Oksana B, Sandborn, William J, and Loftus, Edward V Jr
- Subjects
- *
BIOTHERAPY , *CROHN'S disease , *RESEARCH , *RESEARCH methodology , *EVALUATION research , *TREATMENT effectiveness , *COMPARATIVE studies , *RANDOMIZED controlled trials , *BLIND experiment , *STATISTICAL sampling , *DISEASE remission - Abstract
Background: Active-comparator trials are important to inform patient and physician choice. We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or adalimumab in biologic-naive patients with moderately to severely active Crohn's disease.Methods: We conducted a randomised, double-blind, parallel-group, active-comparator, phase 3b trial (SEAVUE) at 121 hospitals or private practices in 18 countries. We included biologic-naive patients aged 18 years or older with moderately to severely active Crohn's disease and a Crohn's Disease Activity Index (CDAI) score of 220-450, who had not responded to or were intolerant to conventional therapy (or were corticosteroid dependent) and had at least one ulcer of any size at baseline endoscopic evaluation. Eligible patients were randomly assigned (1:1; via an interactive web response system) to receive ustekinumab (approximately 6 mg/kg intravenously on day 0, then 90 mg subcutaneously once every 8 weeks) or adalimumab (160 mg on day 0, 80 mg at 2 weeks, then 40 mg once every 2 weeks, subcutaneously) through week 56. Study treatments were administered as monotherapy and without dose modifications. Patients, investigators, and study site personnel were masked to treatment group assignment. The primary endpoint was the proportion of patients who were in clinical remission (CDAI score <150) at week 52 in the intention-to-treat population (ie, all patients who were randomly assigned to a treatment group). This trial is registered with ClinicalTrials.gov, NCT03464136, and EudraCT, 2017-004209-41.Findings: Between June 28, 2018, and Dec 12, 2019, 633 patients were assessed for eligibility and 386 were enrolled and randomly assigned to receive ustekinumab (n=191) or adalimumab (n=195). 29 (15%) of 191 patients in the ustekinumab group and 46 (24%) of 195 in the adalimumab group discontinued study treatment before week 52. There was no significant difference between the ustekinumab and adalimumab groups in the occurrence of the primary endpoint; at week 52, 124 (65%) of 191 patients in the ustekinumab group versus 119 (61%) of 195 in the adalimumab group were in clinical remission (between-group difference 4%, 95% CI -6 to 14; p=0·42). Safety for both groups was consistent with previous reports. Serious infections were reported in four (2%) of 191 patients in the ustekinumab group and five (3%) of 195 in the adalimumab group. No deaths occurred through week 52 of the study.Interpretation: Both ustekinumab and adalimumab monotherapies were highly effective in this population of biologic-naive patients, with no difference in the primary outcome between the drugs.Funding: Janssen Scientific Affairs. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
22. Specific IgG Response against Mycobacterium avium paratuberculosis in Children and Adults with Crohn’s Disease
- Author
-
Verdier, Julien, Deroche, Louis, Allez, Matthieu, Loy, Caroline, Biet, Franck, Bodier, Christelle C., Bay, Sylvie, Ganneau, Christelle, Matysiak-Budnik, Tamara, Reyrat, Jean Marc, Heyman, Martine, Cerf-Bensussan, Nadine, Ruemmele, Frank M., and Ménard, Sandrine
- Subjects
- *
IMMUNOGLOBULIN G , *MYCOBACTERIUM avium paratuberculosis , *CROHN'S disease , *AGE factors in disease , *IMMUNOGLOBULINS , *GLYCOSYLTRANSFERASES , *BACTERIAL diseases - Abstract
Background and Aims: Presence of serum antibodies against Mycobacterium avium paratuberculosis (MAP) in Crohn’s Disease (CD) as a disease characteristic remains controversial. In the present work, we assessed antibody reactivity of serum and intestinal fluid against four distinct MAP-antigens, including the recently identified MAP-specific lipopentapeptide (L5P). Methods: Immunoglobulin concentrations and specificity against 3 non MAP-specific antigens: glycosyl-transferase-d (GSD), purified protein derivative from MAP (Johnin-PPD), heparin binding haemagglutinin (MAP-HBHA) and one MAP-specific antigen: synthetic L5P were determined by ELISA in gut lavage fluids from adult controls or patients with CD, and in sera of children or adult controls or patients with CD, ulcerative colitis or celiac disease. Results: Total IgA and IgG concentrations were increased in sera of children with CD but were decreased in sera of adults with CD, thereof specificity against MAP antigens was assessed by normalizing immunoglobulin concentrations between samples. In CD patients, IgG reactivity was increased against the four MAP antigens, including L5P in gut lavage fluids but it was only increased against L5P in sera. By contrast, anti-L5P IgG were not increased in patients with ulcerative colitis or celiac disease. Conclusions: A significant increase in anti-L5P IgG is observed in sera of children and adults with CD but not in patients with other intestinal inflammatory diseases. Anti-L5P antibodies may serve as serological marker for CD. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
23. Long‐term efficacy of fibrin glue injection for perianal fistulas in patients with Crohn's disease.
- Author
-
Vidon, Mathias, Munoz‐Bongrand, Nicolas, Lambert, Jérôme, Maggiori, Léon, Zeitoun, Jean‐David, Corte, Hélène, Panis, Yves, Seksik, Philippe, Treton, Xavier, Abramowitz, Laurent, Allez, Matthieu, and Gornet, Jean‐Marc
- Subjects
- *
CROHN'S disease , *FIBRIN tissue adhesive , *INJECTIONS , *ANAL diseases , *OSTOMY , *DISEASE remission ,ANAL surgery - Abstract
Aim: The treatment of perianal fistulas in Crohn's disease remains challenging. Fibrin glue injection has previously shown short‐term efficacy in a randomized controlled trial. No long‐term data are available to assess the benefit of this treatment. Methods: This retrospective multicentre study included all patients with drained fistulas treated by at least one fibrin glue injection between January 2004 and June 2015 in three tertiary French centres. The primary end‐point was the rate of complete clinical remission at 1 year after injection defined by the closure of all fistula tracts with no need for iterative anal surgery or for optimization of immunosuppressants and/or biologics. Results: In all, 119 patients (median age 33 years, complex fistulas 65%, median previous anal surgery two, median Harvey Bradshaw score 3, immunosuppressants exposure 50%, anti‐tumor necrosis factor exposure 60% with median time of administration of 1.1 year) were analysed with a median follow‐up of 18.3 months. The complete clinical remission rate at 1 year was 45.4%. The primary end‐point was achieved in 63% of the cases in the combination therapy group and 37% in other patients. The only predictor of complete clinical remission at 1 year was combination therapy at the time of injection (P = 0.01). The rate of early reintervention after glue injection was 2.5%. The cumulative incidence of iterative anal surgery and ostomy in the whole population was 54% and 5.6% respectively at 5 years. Conclusion: An adjunct of fibrin glue to conventional medical therapy may be an effective and safe treatment for perianal fistulas in patients with Crohn's disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
- Author
-
Wils, Pauline, Seksik, Philippe, Stefanescu, Carmen, Nancey, Stephane, Allez, Matthieu, Pineton de Chambrun, Guillaume, Altwegg, Romain, Gilletta, Cyrielle, Vuitton, Lucine, Viennot, Stéphanie, Serrero, Mélanie, Fumery, Mathurin, Savoye, Guillaume, Collins, Michael, Goutorbe, Felix, Brixi, Hedia, Bouguen, Guillaume, Tavernier, Noémie, Boualit, Medina, and Amiot, Aurélien
- Subjects
- *
INFLAMMATORY bowel diseases , *MISCARRIAGE , *VEDOLIZUMAB , *PREGNANCY outcomes , *COHORT analysis , *PREGNANT women - Abstract
Summary: Background: The prevalence of inflammatory bowel diseases (IBD) is high in women of childbearing age. Achieving clinical remission from conception to delivery using current medications is a major issue in IBD. Aims: To assess maternal and neonatal complications and management of vedolizumab or ustekinumab) in pregnant women with IBD receiving these agents. Methods: We performed a retrospective cohort study among GETAID centres including women with IBD who received ustekinumab or vedolizumab during pregnancy or within the 2 months before conception and compared outcomes to women exposed to anti‐TNF treatment during pregnancy. Results: Seventy‐three pregnancies in 68 women with IBD were analysed: 29 on ustekinumab resulting in 26 (90%) live births, two (7%) spontaneous abortions and one (3%) elective termination; 44 on vedolizumab resulting in 38 (86%) live births, five (11%) spontaneous abortions and one (3%) medical interruption. The control group included 88 pregnancies exposed to anti‐TNF in 76 women with IBD. The median age at conception, the proportion of women who smoked or in clinical activity at conception was comparable between groups. Only the proportion of patients exposed to >2 anti‐TNF agents was significantly increased among the ustekinumab and vedolizumab groups compared to control group (22% and 10% vs 3%, P < 0.005). Rates of prematurity, spontaneous abortion, congenital malformations and maternal complications were comparable between groups. Conclusion: We report 73 pregnancies in patients receiving vedolizumab or ustekinumab without a negative signal on maternal or neonatal outcomes. Further prospective studies are needed on the outcomes of pregnancies with new biologic drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
- Author
-
Chapuis-Biron, Constance, Kirchgesner, Julien, Pariente, Benjamin, Bouhnik, Yoram, Amiot, Aurélien, Viennot, Stéphanie, Serrero, Mélanie, Fumery, Mathurin, Allez, Matthieu, Siproudhis, Laurent, Buisson, Anthony, de Chambrun, Guillaume Pineton, Abitbol, Vered, Nancey, Stéphane, Caillo, Ludovic, Plastaras, Laurianne, Savoye, Guillaume, Chanteloup, Elise, Simon, Marion, and Dib, Nina
- Subjects
- *
THERAPEUTICS , *CROHN'S disease , *TISSUE wounds , *TUMOR necrosis factors , *COHORT analysis , *LOGISTIC regression analysis - Abstract
INTRODUCTION: New therapeutic options for patients with Crohn's disease (CD) with perianal lesions failing anti-tumor necrosis factor (TNF) agents are needed. We aimed to assess the effectiveness of ustekinumab in perianal CD (pCD) and predictors of clinical success in a real-life multicenter cohort. METHODS: We conducted a national multicenter retrospective cohort study in patients with either active or inactive pCD who received ustekinumab. In patients with active pCD at treatment initiation, the success of ustekinumab was defined by clinical success at 6 months assessed by the physician's judgment without additional medical or surgical treatment for pCD. Univariate and multivariable logistic regression analyses were performed to identify predictors of success. In patients with inactive pCD at ustekinumab initiation, the pCD recurrencefree survival was calculated using the Kaplan-Meier method. RESULTS: Two hundred seven patients were included, the mean age was 37.7 years, the mean duration of CD was 14.3 years, andthemean number ofpriorperianal surgerieswas 2.8.Two hundred five (99%) patients had previously been exposed to at least 1 anti-TNF and 58 (28%) to vedolizumab. The median follow-up time was 48 weeks; 56/207 (27%) patients discontinued therapy after a median time of 43 weeks. In patients with active pCD, successwas reached in 57/148 (38.5%) patients. Among patientswith setons at initiation, 29/88 (33%) had a successful removal. The absence of optimizationwas associatedwith treatment success (P50.044, odds ratio 2.74; 95% confidence interval: 0.96-7.82). In multivariable analysis, the number of prior anti-TNF agents (3) was borderline significant (P 5 0.056, odds ratio 0.4; 95%confidence interval: 0.15-1.08). In patients with inactive pCD at initiation, the probability of recurrence-free survival was 86.2% and 75.1% at weeks 26 and 52, respectively. DISCUSSION: Ustekinumab appears as a potential effective therapeutic option in perianal refractory CD. Further prospective studies are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease.
- Author
-
Hammoudi, Nassim, Auzolle, Claire, My-Linh Tran Minh, Boschetti, Gilles, Bezault, Madeleine, Buisson, Anthony, Pariente, Benjamin, Treton, Xavier, Seksik, Philippe, Fumery, Mathurin, Le Bourhis, Lionel, Nancey, Steephane, and Allez, Matthieu
- Subjects
- *
CROHN'S disease , *DISEASE risk factors , *COLONOSCOPY , *ENDOSCOPY , *MEDICAL care - Abstract
INTRODUCTION: Early ileocolonoscopy within the first year after surgery is the gold standard to evaluate recurrence after ileocolonic resection for Crohn's disease (CD). The aim of the study was to evaluate the association between the presence and severity of anastomotic and ileal lesions at early postoperative ileocolonoscopy and long-term outcomes. METHODS: The REMIND group conducted a prospective multicenter study. Patients operated for ileal or ileocolonic CD were included. An ileocolonoscopy was performed 6 months after surgery. An endoscopic score describing separately the anastomotic and ileal lesions was built. Clinical relapse was defined by the CD-related symptoms, confirmed by imaging, endoscopy or therapeutic intensification; CD-related complications; or subsequent surgery. RESULTS: Among 225 included patients, long-term follow-up was available in 193 (median follow-up: 3.82 years [interquartile range: 2.56-5.41]). Median clinical recurrence-free survival was 47.6 months. Clinical recurrence-free survival was significantly shorter in patients with ileal lesions at early postoperative endoscopy whatever their severity was (I(1) or I(2,3,4)) as compared to patients without ileal lesions (I(0)) (I(0) vs I(2,3,4): P = 0.0003; I(0) vs I(1): P = 0.0008 and I(1) vs I(2,3,4): P = 0.43). Patients with exclusively ileal lesions (A(0)I(1,2,3,4)) had poorer clinical long-term outcomes than patients with exclusively anastomotic lesions (A(1,2,3)I(0)) (P = 0.009). DISCUSSION: A score describing separately the anastomotic and ileal lesions might be more appropriate to define postoperative endoscopic recurrence. Our data suggest that patients with ileal lesions, including mild ones (I(1)), could beneficiate from treatment step-up to improve long-term outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factor.
- Author
-
Alric, Hadrien, Amiot, Aurélien, Kirchgesner, Julien, Tréton, Xavier, Allez, Matthieu, Bouhnik, Yoram, Beaugerie, Laurent, Carbonnel, Franck, and Meyer, Antoine
- Subjects
- *
CROHN'S disease , *DISEASE remission , *VEDOLIZUMAB , *INFLAMMATORY bowel diseases , *NECROSIS - Abstract
Summary: Background: There is no head‐to‐head trial comparing ustekinumab and vedolizumab in patients with Crohn's disease (CD) refractory to anti‐tumour necrosis factor (anti‐TNF). Aim: To compare the effectiveness and safety of ustekinumab and vedolizumab in patients with CD refractory to anti‐TNF in a multicentre retrospective observational cohort. Methods: All consecutive patients with CD refractory or intolerant to anti‐TNF who initiated either vedolizumab or ustekinumab were included between May 2014 and August 2018. Clinical remission, steroid‐free clinical remission (SFCR) and treatment persistence were assessed at week 48 with intention‐to‐treat analysis and propensity scores weighted comparison. Results: A total of 239 patients were included, 107 received ustekinumab and 132 received vedolizumab. At week 48, ustekinumab was associated with a higher clinical remission rate (54.4% vs 38.3%; odds ratios, OR = 1.92, 95% CI [1.09‐3.39]) and treatment persistence (71.5% vs 49.7%; OR = 2.54, 95% CI [1.40‐4.62]) than vedolizumab. The rate of SFCR did not differ significantly between ustekinumab and vedolizumab (44.7% vs 34.0%; OR = 1.57, 95% CI [0.88‐2.79]). Subgroup analyses showed that ustekinumab was associated with a higher clinical remission rates at week 48 in patients with ileal location (OR = 3.49, 95% CI [1.33‐9.17) and penetrating behaviour (OR = 6.58, 95% CI [1.91‐22.68]). Regardless of the treatment group, combination therapy at initiation was associated with a higher clinical remission rate at week 48 (OR = 1.93, 95% CI [1.09‐3.43]). Conclusion: This study suggests that ustekinumab is associated with a higher rate of clinical remission and treatment persistence than vedolizumab after 48 weeks of follow‐up, in patients with CD refractory or intolerant to anti‐TNF. The rate of SFCR was not significantly different. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Assessing the effect of genetic markers on drug immunogenicity from a mechanistic model-based approach.
- Author
-
Duhazé, Julianne, Caubet, Miguel, Hässler, Signe, Bachelet, Delphine, Allez, Matthieu, Deisenhammer, Florian, Fogdell-Hahn, Anna, Gleizes, Aude, Hacein-Bey-Abina, Salima, Mariette, Xavier, Pallardy, Marc, Broët, Philippe, and ABIRISK Consortium
- Subjects
- *
GENETIC markers , *LOG-rank test , *ANTIBODY formation , *IMMUNE response - Abstract
Background: With the growth in use of biotherapic drugs in various medical fields, the occurrence of anti-drug antibodies represents nowadays a serious issue. This immune response against a drug can be due either to pre-existing antibodies or to the novel production of antibodies from B-cell clones by a fraction of the exposed subjects. Identifying genetic markers associated with the immunogenicity of biotherapeutic drugs may provide new opportunities for risk stratification before the introduction of the drug. However, real-world investigations should take into account that the population under study is a mixture of pre-immune, immune-reactive and immune-tolerant subjects.Method: In this work, we propose a novel test for assessing the effect of genetic markers on drug immunogenicity taking into account that the population under study is a mixed one. This test statistic is derived from a novel two-part semiparametric improper survival model which relies on immunological mechanistic considerations.Results: Simulation results show the good behavior of the proposed statistic as compared to a two-part logrank test. In a study on drug immunogenicity, our results highlighted findings that would have been discarded when considering classical tests.Conclusion: We propose a novel test that can be used for analyzing drug immunogenicity and is easy to implement with standard softwares. This test is also applicable for situations where one wants to test the equality of improper survival distributions of semi-continuous outcomes between two or more independent groups. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
29. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment.
- Author
-
Courau, Tristan, Bonnereau, Julie, Chicoteau, Justine, Bottois, Hugo, Remark, Romain, Miranda, Laura Assante, Toubert, Antoine, Blery, Mathieu, Aparicio, Thomas, Allez, Matthieu, and Le Bourhis, Lionel
- Subjects
- *
COLON tumors , *KILLER cells , *CANCER treatment , *MICA , *TUMOR-infiltrating immune cells , *HEREDITARY nonpolyposis colorectal cancer - Abstract
Background: Immunotherapies still fail to benefit colorectal cancer (CRC) patients. Relevant functional assays aimed at studying these failures and the efficacy of cancer immunotherapy in human are scarce. 3D tumor cultures, called tumor organoids or spheroids, represent interesting models to study cancer treatments and could help to challenge these issues. Methods: We analyzed heterotypic cocultures of human colon tumor-derived spheroids with immune cells to assess the infiltration, activation and function of T and NK cells toward human colorectal tumors in vitro. Results: We showed that allogeneic T and NK cells rapidly infiltrated cell line-derived spheroids, inducing immunemediated tumor cell apoptosis and spheroid destruction. NKG2D, a key activator of cytotoxic responses, was engaged on infiltrating cells. We thus assessed the therapeutic potential of an antibody targeting the specific ligands of NKG2D, MICA and MICB, in this system. Anti-MICA/B enhanced immune-dependent destruction of tumor spheroid by driving an increased NK cells infiltration and activation. Interestingly, tumor cells reacted to immune infiltration by upregulating HLA-E, ligand of the inhibitory receptor NKG2A expressed by CD8 and NK cells. NKG2A was increased after anti-MICA/B treatment and, accordingly, combination of anti-MICA/B and anti-NKG2A was synergistic. These observations were ultimately confirmed in a clinical relevant model of coculture between CRC patients-derived spheroids and autologous tumor-infiltrating lymphocytes. Conclusions: Altogether, we show that tumor spheroids represent a relevant tool to study tumor-lymphocyte interactions on human tissues and revealed the antitumor potential of immunomodulatory antibodies targeting MICA/B and NKG2A. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
30. Simultaneous quantification and structural characterization of monoclonal antibodies after administration using capillary zone electrophoresis-tandem mass spectrometry.
- Author
-
Reinert, Tessa, Gahoual, Rabah, Mignet, Nathalie, Kulus, Alexandre, Allez, Matthieu, Houzé, Pascal, and François, Yannis-Nicolas
- Subjects
- *
CAPILLARY electrophoresis , *MONOCLONAL antibodies , *MASS spectrometry , *TANDEM mass spectrometry , *CROHN'S disease , *POST-translational modification - Abstract
Monoclonal antibodies (mAbs) are demonstrating major success in various therapeutic areas such as oncology and the treatment of immune disorders. Over the past two decades, novel analytical methodologies allowed to address the challenges of mAbs characterization in the context of their production. However, after administration only their quantification is performed and insights regarding their structural evolution remain limited. For instance, clinical practice has recently highlighted significant inter-patient differences in mAb clearance and unexpected clinical responses, without providing alternative interpretations. Here, we report the development of a novel analytical strategy based on capillary zone electrophoresis coupled to tandem mass spectrometry (CE-MS/MS) for the simultaneous absolute quantification and structural characterization of infliximab (IFX) in human serum. CE-MS/MS quantification was validated over the range 0.4–25 µg·mL-1 corresponding to the IFX therapeutic window and achieved a LOQ of 0.22 µg·mL-1 (1.5 nM) while demonstrating outstanding specificity compared to the ELISA assay. CE-MS/MS allowed structural characterization and estimation of the relative abundance of the six major N-glycosylations expressed by IFX. In addition, the results allowed characterization and determination of the level of modification of post-translational modifications (PTMs) hotspots including deamidation of 4 asparagine and isomerization of 2 aspartate. Concerning N-glycosylation and PTMs, a new normalization strategy was developed to measure the variation of modification levels that occur strictly during the residence time of IFX in the patient's system, overcoming artefactual modifications induced by sample treatment and/or storage. The CE-MS/MS methodology was applied to the analysis of samples from patients with Crohn's disease. The data identified a gradual deamidation of a particular asparagine residue located in the complementary determining region that correlated with IFX residence time, while the evolution of IFX concentration showed significant variability among patients. [Display omitted] • A novel CE-MS/MS analytical strategy was developed for mAbs analysis in serum. • CE-MS/MS absolute quantification of mAbs in serum was validated as low as 1.5 nM. • Structural characterization and relative quantification of N-glycosylation obtained. • Simultaneous characterizations of mAbs PTMs achieved in serum using CE-MS/MS data. • CE-MS/MS method was applied to patient serums treated using infliximab. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.
- Author
-
Dubash, Sayam, Marianayagam, Thiraupathy, Tinazzi, Ilaria, Al-Araimi, Tariq, Pagnoux, Christian, Weizman, Adam V, Richette, Pascal, Minh, My-Linh Tran, Allez, Matthieu, Singh, Animesh, Ciccia, Francesco, Hamlin, John, Tan, Ai Lyn, Marzo-Ortega, Helena, and McGonagle, Dennis
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *HOSPITAL care , *INFLAMMATORY bowel diseases , *INTESTINAL diseases , *MAGNETIC resonance imaging , *MONOCLONAL antibodies , *OSTEITIS , *SPONDYLOARTHROPATHIES , *TENDON injuries , *TUMOR necrosis factors , *ULTRASONIC imaging , *TERMINATION of treatment , *TREATMENT effectiveness , *SEVERITY of illness index , *CHEMICAL inhibitors , *THERAPEUTICS - Abstract
Objectives Vedolizumab (VDZ) blocks α4β7 integrin and is licenced for the treatment of IBD. It has been associated with mild SpA-related features, including sacroiliitis and synovitis. Herein we report a series of cases demonstrating the emergence of severe SpA-associated enthesitis/osteitis following successful IBD therapy with VDZ. Methods We evaluated 11 VDZ-treated patients with IBD across seven centres who developed severe active SpA and/or enthesopathy, with the aim of characterizing the VDZ-associated SpA or entheseal flares. Imaging features demonstrating particularly severe disease were recorded. Results De novo SpA developed in 9 of 11 patients and flare of known SpA in 2 patients, with 4 patients requiring hospitalization due to disease severity. Available data showed that one of seven cases were HLA-B27 positive. The median time from VDZ initiation to flare was 12 weeks, with IBD well controlled in 7 of 10 patients (no data for 1 patient) at flare. Severe SpA enthesitis/osteitis was evident on MRI or US, including acute sacroiliitis (n = 5), extensive vertebral osteitis (n = 1), peri-facetal oedema (n = 1) and isolated peripheral enthesitis (n = 3). Due to arthritis severity, VDZ was discontinued in 9 of 11 patients and a change in therapy, including alternative anti-TNF, was initiated. Conclusion Severe SpA, predominantly HLA-B27 negative, with osteitis/enthesitis may occur under successful VDZ treatment for IBD, including in subjects with prior anti-TNF therapy for intestinal disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
32. Male gender, active smoking and previous intestinal resection are risk factors for post‐operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study.
- Author
-
Auzolle, Claire, Nancey, Stephane, Tran‐Minh, My‐Linh, Buisson, Anthony, Pariente, Benjamin, Stefanescu, Carmen, Fumery, Mathurin, Marteau, Philippe, Treton, Xavier, Hammoudi, Nassim, Jouven, Xavier, Seksik, Philippe, Allez, Matthieu, Cattan, Pierre, Chirica, Mirea, Munoz‐Bongrand, Nicolas, Corte, Hélène, Gornet, Jean‐Marc, Baudry, Clotilde, and Lourenco, Nelson
- Subjects
- *
CROHN'S disease , *SURGICAL complications , *INFLAMMATORY bowel diseases , *ULCERATIVE colitis , *OPERATIVE surgery - Abstract
Summary: Background: After ileocaecal resection for Crohn's disease (CD), inflammatory lesions frequently recur on the anastomosis and/or on the neo‐terminal ileum. Aim: To identify predictors of early post‐operative endoscopic recurrence. Methods: From September 2010 to September 2017, the REMIND group conducted a prospective nationwide study in nine French academic centres. Data were collected at the time of surgery and endoscopy, performed 6‐12 months after surgery. Endoscopic recurrence was defined as a Rutgeerts score ≥i2. Baseline factors associated with endoscopic recurrence were searched by univariate and multivariate regression analysis. Results: Two hundred and eighty‐nine CD patients were included. Endoscopy within 1 year following surgery was performed in 225 (78%) patients (104M/121F). Mean age and disease duration were 35 (12.2) and 8.8 (8.9) years respectively. Seventy (32%) patients were active smokers at surgery. One hundred and forty‐two (63%) patients received at least one anti‐TNF therapy before surgery. After surgery, 40 (18%) patients received thiopurines and 66 (29%) received an anti‐TNF agent. Endoscopic recurrence occurred in 107 (47%) patients. In multivariate analysis, male gender (OR = 2.48 [IC 95% 1.40‐4.46]), active smoking at surgery (OR = 2.65 [IC 95% 1.44‐4.97]) and previous resection (OR = 3.03 [IC 95% 1.36‐7.12]) were associated with a higher risk of endoscopic recurrence. Inversely, post‐operative anti‐TNF treatment decreased the risk of endoscopic recurrence (OR = 0.50 [IC 95% 0.25‐0.96]). Conclusions: Male gender, active smoking at surgery and previous intestinal resection are associated with a higher risk of endoscopic post‐operative recurrence, while post‐operative anti‐TNF treatment is associated with a lower risk. Linked Content This article is linked to Yamamoto and Kotze, and Imperatore et al papers. To view these articles visit https://doi.org/10.1111/apt.14985 and https://doi.org/10.1111/apt.14989. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
33. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
- Author
-
Carrat, F., Seksik, P., Colombel, J.‐F., Peyrin‐Biroulet, L., Beaugerie, L., Colombel, Jean‐Frédéric, Cosnes, Jacques, Gendre, Jean‐Pierre, Lémann, Marc, Hébuterne, Xavier, Cortot, Antoine, Bouhnik, Yoram, Laharie, David, Dupas, Jean Louis, Flourié, Bernard, Lerebours, Eric, Beaugerie, Laurent, Peyrin‐Biroulet, Laurent, Allez, Matthieu, and Messing, Bernard
- Subjects
- *
COLON cancer risk factors , *INFLAMMATORY bowel diseases , *COLITIS diagnosis , *CANCER treatment , *DRUG efficacy , *PATIENTS - Abstract
Background Whether aminosalicylates or thiopurines reduce the risk of colorectal cancer ( CRC) in inflammatory bowel ( IBD) disease is controversial. Aim To assess simultaneously the chemopreventive effect of aminosalicylates or thiopurines in a case-control study nested in the CESAME observational cohort that enrolled consecutive patients with IBD between May 2004 and June 2005. Patients were followed up to December 2007. Methods Study population comprised 144 case patients who developed CRC from the diagnosis of IBD (65 and 79 cases diagnosed, respectively, before and from 2004, starting year of the prospective observational period of CESAME) and 286 controls matched for gender, age, IBD subtype and year of diagnosis, and cumulative extent of colitis. Exposure to aminosalicylates or thiopurines was defined by an exposure to the treatment during the year of the diagnosis of cancer. The propensity of receiving 5- ASA and thiopurines was quantified by a composite score taking into account patient and IBD characteristics. The role of aminosalicylates or thiopurines was assessed by multivariate analysis. Propensity scores and the history of primary sclerosing cholangitis were entered into the multivariate model for adjustment. Results By multivariate analysis adjusted for propensity, a significant protective effect of exposure to drugs during the year of cancer was found for aminosalicylates ( OR = 0.587, 95% CI: 0.367-0.937, P = 0.0257), but not for thiopurines ( OR = 0.762, 95% CI: 0.432-1.343, P = 0.3468). Conclusion In a case-control study nested in the CESAME cohort, a significant decrease in the risk of colorectal cancer in IBD was associated with exposure to aminosalicylates, not to thiopurines. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
34. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
- Author
-
Bourrier, A., Carrat, F., Colombel, J.‐F., Bouvier, A.‐M., Abitbol, V., Marteau, P., Cosnes, J., Simon, T., Peyrin‐Biroulet, L., Beaugerie, L., Gendre, Jean‐Pierre, Lémann, Marc, Hébuterne, Xavier, Cortot, Antoine, Bouhnik, Yoram, Laharie, David, Dupas, Jean Louis, Flourié, Bernard, Lerebours, Eric, and Allez, Matthieu
- Subjects
- *
URINARY tract infections , *INFLAMMATORY bowel disease treatment , *INFLAMMATION treatment , *INFLAMMATORY bowel diseases , *INFLAMMATION , *PATIENTS , *DISEASE risk factors - Abstract
Background The risk of urinary tract cancers, including kidney and bladder cancers, was increased in transplant recipients receiving thiopurines. Aim To assess the risk of urinary tract cancers in patients with inflammatory bowel disease (IBD) receiving thiopurines in the CESAME observational cohort. Methods Between May 2004 and June 2005, 19 486 patients with IBD, 30.1% of whom were receiving thiopurines, were enrolled. Median follow-up was 35 months (IQR: 29-40). Results Ten and six patients developed respectively kidney and bladder cancer. The incidence rates of urinary tract cancer were 0.48/1000 patient-years in patients receiving thiopurines (95% CI: 0.21-0.95), 0.10/1000 patient-years in patients who discontinued thiopurines (95% CI: 0.00-0.56) and 0.30/1000 patient-years in patients never treated with thiopurines (95% CI: 0.12-0.62) at entry. The standardised incidence ratio of urinary tract cancer was 3.40 (95% CI: 1.47-6.71, P = 0.006) in patients receiving thiopurines, 0.64 (95% CI: 0.01-3.56, P = 0.92) in patients previously exposed to thiopurines and 1.17 (95% CI: 0.47-12.42, P = 0.78) in patients never treated with thiopurines. The multivariate-adjusted hazard ratio (HR) of urinary tract cancer between patients receiving thiopurines and those not receiving thiopurines was 2.82 (95% CI: 1.04-7.68, P = 0.04). Other significant risk factors were male gender (HR: 3.98, 95% CI: 1.12-14.10, P = 0.03) and increasing age (HR after 65 years (ref <50): 13.26, 95% CI: 3.52-50.03, P = 0.0001). Conclusion Patients with IBD receiving thiopurines have an increased risk of urinary tract cancers. Clinically relevant excess risk is observed in older men. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
35. Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.
- Author
-
Ternant, David, Berkane, Zahir, Picon, Laurence, Gouilleux-Gruart, Valérie, Colombel, Jean-Frédéric, Allez, Matthieu, Louis, Edouard, and Paintaud, Gilles
- Subjects
- *
INFLAMMATORY bowel disease treatment , *INFLAMMATION , *PHARMACOKINETICS , *INFLIXIMAB , *DISEASE relapse , *CROHN'S disease , *GENOTYPES , *PATIENTS - Abstract
Background and Objectives: Infliximab is a monoclonal anti-tumor necrosis factor-α (anti-TNFα) antibody that profoundly modified the treatment of Crohn's disease (CD). The polymorphism of Fc fragment of IgG, low affinity IIIa, receptor (CD16a) [ FCGR3A] influences the biological response to infliximab in patients with CD. Our aim was to study its influence on infliximab pharmacokinetics and risk of relapse after infliximab discontinuation. Methods: In 111 CD patients in remission, infliximab was discontinued and its concentrations were measured for 30 months or until relapse. Infliximab pharmacokinetics were described using monocompartmental population modeling. Results: The elimination rate of infliximab increased with C-reactive protein (CRP) [ p = 0.00018] and was 16 % higher in FCGR3A-158V/V patients than in F carriers ( p = 0.0028). Risk of relapse was higher in patients with baseline CRP ≥5 mg/L than in those with a lower value ( p = 0.0000029). In addition, there was a first-order interaction between CRP and the FCGR3A genotype; in patients with high CRP, risk of relapse was higher for V/V patients than for F carriers (hazard ratio 4.80 and 2.84 for V/V and F carriers, respectively; p = 0.013). Conclusion: Both increased inflammation and FCGR3A-158V/V genotype are associated with increased infliximab elimination and risk of relapse after infliximab discontinuation in patients with CD. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
36. Endoscopic and Clinical Recurrences After Laparoscopic or Open Ileocolic Resection in Crohn's Disease.
- Author
-
Bellinger, Justine, Munoz-Bongrand, Nicolas, Pariente, Benjamin, Baudry, Clotilde, Chirica, Mircea, Gornet, Jean-Marc, Allez, Matthieu, and Cattan, Pierre
- Subjects
- *
CROHN'S disease , *SURGICAL excision , *ENDOSCOPIC surgery , *FOLLOW-up studies (Medicine) , *COLONOSCOPY , *ABDOMINAL surgery , *DISEASE relapse , *STANDARD deviations - Abstract
Background: After ileocolic resection in Crohn's disease, studies concerning the influence of the laparoscopic or open approach on clinical and endoscopic recurrences are scarce. Patients and Methods: In a prospective database, we identified all patients operated on between 2004 and 2012 for primary ileocolic resection in Crohn's disease, with at least 6 months of follow-up. The rates of endoscopic recurrence during the first postoperative year and the clinical recurrence at any time during follow-up were measured and compared after the laparoscopic or open approach. Results: Sixty-two patients (mean±standard deviation age, 33.5±12.7 years; 35 females) were operated on through laparoscopy ( n=28) or laparotomy ( n=34). Medical treatment, evolution and phenotype of disease, and postoperative course were comparable in both groups. Mean±standard deviation follow-up was 3.5±1.9 years. Ileocolonoscopy was available in 46 (74.2%) patients. Normal endoscopy or minor recurrence (i0 or i1 grade) was significantly more frequent after laparoscopy (14/24 [58.3%]) versus laparotomy (5/22 [22.7%]) ( P=.019). Clinical recurrence was comparable at 1 year ( P=.116) and at the end of follow-up ( P=.799) after laparoscopy (28.6% and 50%, respectively) or laparotomy (11.8% and 55.9%, respectively). Conclusions: After resection, normal or minor endoscopic lesions (i0 or i1 grade) were more frequent after laparoscopy than after laparotomy. However, clinical recurrence was similar after both techniques. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
37. Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease.
- Author
-
Zéphir, Hélène, Gower-Rousseau, Corinne, Salleron, Julia, Simon, Olivier, Debouverie, Marc, Le Page, Emmanuelle, Bouhnik, Yoram, Lebrun-Frenay, Christine, Papeix, Caroline, Vigneron, Benoît, Allez, Matthieu, Prin, Lionel, Cosnes, Jacques, Vermersch, Patrick, and Colombel, Jean-Frédéric
- Subjects
- *
MULTIPLE sclerosis , *DEMYELINATION , *MYELIN sheath diseases , *INFLAMMATORY bowel diseases , *GASTROENTERITIS - Abstract
An association between multiple sclerosis (MS) and inflammatory bowel disease (IBD) has been suggested. The purpose of this study was to compare the disease course of patients with both MS and IBD with that of patients with isolated MS or isolated IBD. Sixty-six MS-IBD patients were identified and were matched with 251 isolated MS and 257 isolated IBD controls. Main outcomes were scores using the Expanded Disability Status Scale (EDSS) in MS and extent of disease extension in IBD at last clinical evaluation. After a median 12 years of disease duration, the median EDSS and the percentages of patients reaching an EDSS of 3.0 and 4.0 were significantly lower in MS-IBD patients than in controls. MS had no impact on IBD. MS course appears to be milder in patients with concomitant IBD. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
38. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents.
- Author
-
Fiorino, Gionata, Danese, Silvio, Pariente, Benjamin, and Allez, Matthieu
- Subjects
- *
AUTOIMMUNE diseases , *INFLAMMATORY bowel diseases , *PSORIASIS , *SKIN inflammation , *TUMOR necrosis factors , *RHEUMATOID arthritis , *PATIENTS - Abstract
Abstract: Reports of autoimmune diseases, including psoriasis- and dermatitis-like skin reactions with anti-tumor necrosis factor-α (TNF-α), are increasing, likely a reflection of the growing use of these agents. This paradoxical phenomenon can no longer be considered rare, with some studies providing incidence estimates of greater than 10%. This paradoxical inflammation has been reported in patients receiving treatment with anti-TNF-α agents for a variety of inflammatory conditions, including inflammatory bowel disease, psoriasis and rheumatoid arthritis and appears to be a class effect. Moreover, there have recently been reports of autoimmune arthralgia occurring in patients receiving anti-TNF-α agents. Further studies are necessary to determine the true incidence of this phenomenon and to identify those patients most likely to be at risk. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
39. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.
- Author
-
Laharie, David, Bourreille, Arnaud, Branche, Julien, Allez, Matthieu, Bouhnik, Yaram, Filippi, Jerome, Zerbib, Frank, Savaye, Guillaume, Nachury, Maria, Moreau, Jacques, Delchier, Jean-Charles, Cosnes, Jacques, Ricart, Elena, Dewit, Olivier, Lopez-Sanroman, Antonio, Dupas, Jean-Louis, Carbannel, Franck, Bommelaer, Gilles, Coffin, Benoit, and Roblin, Xavier
- Subjects
- *
CLINICAL trials , *INFLIXIMAB , *ULCERATIVE colitis , *STEROIDS , *PHYSICIANS - Abstract
The article discusses a randomized clinical trial which compared the effectiveness and safety of ciclosporin and infliximab in patients with severe ulcerative colitis refractory to intravenous steroids. Results of the trial revealed that ciclosporin is not more effective in comparison to infliximab. It is suggested that the choice of treatment should be guided by physician and center experience.
- Published
- 2012
- Full Text
- View/download PDF
40. Genotype/Phenotype Analyses for 53 Crohn's Disease Associated Genetic Polymorphisms.
- Author
-
Jung, Camille, Colombel, Jean-Frédéric, Lemann, Marc, Beaugerie, Laurent, Allez, Matthieu, Cosnes, Jacques, Vernier-Massouille, Gwenola, Gornet, Jean-Marc, Gendre, Jean-Pierre, Cezard, Jean-Pierre, Ruemmele, Frank M., Turck, Dominique, Merlin, Françoise, Zouali, Habib, Libersa, Christian, Dieudé, Philippe, Soufir, Nadem, Thomas, Gilles, and Hugot, Jean-Pierre
- Subjects
- *
GENETIC polymorphisms , *CROHN'S disease , *POPULATION genetics , *CLINICAL medicine , *PEDIATRICS - Abstract
Background & Aims: Recent studies reported a role for more than 70 genes or loci in the susceptibility to Crohn's disease (CD). However, the impact of these associations in clinical practice remains to be defined. The aim of the study was to analyse the relationship between genotypes and phenotypes for the main 53 CD-associated polymorphisms. Method: A cohort of 798 CD patients with a median follow up of 7 years was recruited by tertiary adult and paediatric gastroenterological centres. A detailed phenotypic description of the disease was recorded, including clinical presentation, response to treatments and complications. The participants were genotyped for 53 CD-associated variants previously reported in the literature and correlations with clinical sub-phenotypes were searched for. A replication cohort consisting of 722 CD patients was used to further explore the putative associations. Results: The NOD2 rare variants were associated with an earlier age at diagnosis (p = 0.0001) and an ileal involvement (OR = 2.25[1.49-3.41] and 2.77 [1.71-4.50] for rs2066844 and rs2066847, respectively). Colonic lesions were positively associated with the risk alleles of IL23R rs11209026 (OR = 2.25 [1.13-4.51]) and 6q21 rs7746082 (OR = 1.60 [1.10-2.34] and negatively associated with the risk alleles of IRGM rs13361189 (OR = 0.29 [0.11-0.74]) and DEFB1 rs11362 (OR = 0.50 [0.30- 0.80]). The ATG16L1 and IRGM variants were associated with a non-inflammatory behaviour (OR = 1.75 [1.22-2.53] and OR = 1.50 [1.04-2.16] respectively). However, these associations lost significance after multiple testing corrections. The protective effect of the IRGM risk allele on colonic lesions was the only association replicated in the second cohort (p = 0.03). Conclusions: It is not recommended to genotype the studied polymorphisms in routine practice. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
41. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: Biological roles and effects of TNF and TNF antagonists
- Author
-
Chowers, Yehuda, Sturm, Andreas, Sans, Miquel, Papadakis, Konstantinos, Gazouli, Maria, Harbord, Marcus, Jahnel, Jörg, Mantzaris, Gerassimos J., Meier, Johannes, Mottet, Christian, Peyrin-Biroulet, Laurent, and Allez, Matthieu
- Subjects
- *
ENZYME-linked immunosorbent assay , *EXTRACORPOREAL carbon dioxide removal , *INFLAMMATORY bowel disease treatment , *TUMOR necrosis factors , *CHEMICAL inhibitors , *DRUG efficacy , *BIOCHEMICAL mechanism of action , *INFLAMMATION , *TUMOR treatment - Abstract
Abstract: This second section of the first ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases addresses the biological roles of TNFα and the effects and mechanisms of action of TNFα antagonists. Mechanisms underlying their failure, including induction of TNF-independent inflammatory pathways and phenomena of paradoxical inflammation are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
42. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection
- Author
-
Ben-Horin, Shomron, Margalit, Maya, Bossuyt, Peter, Maul, Jochen, Shapira, Yami, Bojic, Daniela, Chermesh, Irit, Al-Rifai, Ahmad, Schoepfer, Alain, Bosani, Matteo, Allez, Matthieu, Lakatos, Peter Laszlo, Bossa, Fabrizio, Eser, Alexander, Stefanelli, Tommaso, Carbonnel, Franck, Katsanos, Konstantinos, Checchin, Davide, de Miera, Inés Sáenz, and Reinisch, Walter
- Subjects
- *
DISEASE prevalence , *INFLAMMATORY bowel diseases , *CLOSTRIDIUM diseases , *RETROSPECTIVE studies , *ENDOSCOPY , *IMMUNOSUPPRESSIVE agents , *HEALTH outcome assessment - Abstract
Abstract: Background and aim: Limited data suggests that pseudomembranes are uncommon in patients with inflammatory bowel disease (IBD) and C. difficile associated disease (CDAD), but the reason for this is unknown. We aimed to evaluate the rate of pseudomembranes in this population, identify predictive factors for pseudomembranes'' presence and assess its clinical impact. Methods: This was a sub-study of a retrospective European Crohn''s & Colitis Organization (ECCO) multi-center study on the outcome of hospitalized IBD patients with C. difficile. The present study included only patients who underwent lower endoscopy during hospitalization, and compared demographic and clinical parameters in the group of patients with discernable pseudomembranes versus those without. Results: Out of 155 patients in the original cohort, 93 patients underwent lower endoscopy and constituted the study population. Endoscopic pseudomembranes were found in 12 (13%) of these patients. Patients with pseudomembranes presented more commonly with fever (p =0.02) compared to patients without pseudomembranes. No difference between the two groups was found with respect to the use of immunosuppressant drugs, background demographics or disease characteristics. Neither was there a difference between the group with or without pseudomembranes in the frequency of severe adverse clinical outcome or in the duration of hospitalization. On multi-variate analysis the presence of fever remained independently associated with the finding of pseudomembranes (OR 6, 95% CI 1.2–32, p =0.03). Conclusions: This study documents that hospitalized IBD patients with CDAD have low rate of endoscopic pseudomembranes, which is not accounted for by the use of immunosuppressant drugs. IBD patients with CDAD and discernable pseudomembranes more commonly present with fever, but their clinical outcome is similar to patients without pseudomembranes. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
43. Certolizumab pegol – A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn’s disease.
- Author
-
Hurabielle, Charlotte, Schneider, Pierre, Baudry, Clotilde, Bagot, Martine, Allez, Matthieu, and Viguier, Manuelle
- Subjects
- *
CROHN'S disease , *MONOCLONAL antibodies , *PYODERMA gangrenosum , *CYCLOSPORINS , *STEROID drugs , *DISEASES in women - Abstract
Systemic steroids, in association or not with cyclosporin, are indicated for the treatment of large or widespread Pyoderma gangrenosum (PG). We report the case of a 27-year-old woman with a 15-year history of severe Crohn’s disease, who developed a severe and disseminated PG, refractory to multiple lines of treatment. Infliximab and adalimumab were contraindicated, either because of allergy or of ineffectiveness on Crohn’s disease. The addition of certolizumab pegol to the baseline treatment, associating systemic steroids and tacrolimus, finally allowed the complete healing of PG. Oral prednisone was stopped and tacrolimus was decreased, without any cutaneous or digestive relapse. Certolizumab pegol could be an alternative therapy in the treatment of PG in case of intolerance or ineffectiveness of the other anti-tumor necrosis factor (anti-TNF) therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
44. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease.
- Author
-
Barnich, Nicolas, Carvalho, Frédéric A., Glasser, Anne-Lise, Darcha, Claude, Jantscheff, Peter, Allez, Matthieu, Peeters, Harald, Bommelaer, Gilles, Desreumaux, Pierre, Colombel, Jean-Frédéric, and Darfeuille-Michaud, Arlette
- Subjects
- *
MEDICAL research , *CROHN'S disease , *ESCHERICHIA coli , *EPITHELIAL cells , *CELL adhesion , *INFLAMMATORY bowel diseases - Abstract
The ileal mucosa of Crohn disease (CD) patients is abnormally colonized by adherent-invasive E. coli (AIEC) that are able to adhere to and invade intestinal epithelial cells. Here, we show that CD-associated AIEC strains adhere to the brush border of primary ileal enterocytes isolated from CD patients but not controls without inflammatory bowel disease. AIEC adhesion is dependent on type 1 pili expression on the bacterial surface and on carcinoembryonic antigenrelated cell adhesion molecule 6 (CEACAM6) expression on the apical surface of ileal epithelial cells. We report also that CEACAM6 acts as a receptor for AIEC adhesion and is abnormally expressed by ileal epithelial cells in CD patients. In addition, our in vitro studies show that there is increased CEACAM6 expression in cultured intestinal epithelial cells after IFN- or TNF- stimulation and after infection with AIEC bacteria, indicating that AIEC can promote its own colonization in CD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
45. Accessory cell function of airway epithelial cells.
- Author
-
Oei, Erwin, Kalb, Thomas, Beuria, Prarthana, Allez, Matthieu, Nakazawa, Atsushi, Azuma, Miyuki, Timony, Michael, Stuart, Zanetta, Houchu Chen, and Sperber, Kirk
- Subjects
- *
ANTIGEN presenting cells , *EPITHELIAL cells , *AIRWAY (Anatomy) , *LUNG physiology , *RAGWEEDS , *LYMPHOCYTES - Abstract
We previously demonstrated that airway epithelial cells (AECs) have many features of accessory cells, including expression of class II molecules CD80 and CD86 and functional Fcγ receptors. We have extended these studies to show that freshly isolated AECs have mRNA for cathepsins S, V, and H [proteases important in antigen (Ag) presentation], invariant chain, human leukocyte antigen (HLA)-DM-α and HLADM-β, and CLIP, an invariant chain breakdown product. A physiologically relevant Ag, ragweed, was colocalized with HLA-DR in AECs, and its uptake was increased by granulocyte-macrophage colony-stimulating factor and IFN-γ treatments, which had no effect on CD80 and CD86 expression. We demonstrate the presence of other costimulatory molecules, including B7h and B7-H1, on AECs and the increased expression of B7-H1 on AECs after treatment with granulocyte-macrophage colony-stimulating factor and IFN-γ. Finally, we compared T cell proliferation after allostimulation with AECs and dendritic cells (DCs). The precursor frequency of peripheral blood T cells responding to AECs was 0.264% compared with 0.55% for DCs. DCs stimulated CD45RO+, CD45RA+, CCR7+ and CCR7-CD4+, and CD8+ T cells, whereas AECs stimulated only CD45RO+, CD45RA-, CCR7-, CD4+, and CD8+ T cells. There was no difference in cytokine production, type of memory T cells stimulated (effector vs. long-term memory), or apoptosis by T cells cocultured with AECs and DCs. The localization of AECs exposed to the external environment may make them important in the regulation of local immune responses. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
46. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment.
- Author
-
Courau, Tristan, Bonnereau, Julie, Chicoteau, Justine, Bottois, Hugo, Remark, Romain, Assante Miranda, Laura, Toubert, Antoine, Blery, Mathieu, Aparicio, Thomas, Allez, Matthieu, and Le Bourhis, Lionel
- Subjects
- *
CELLS , *CANCER treatment , *KILLER cells - Abstract
Background: Immunotherapies still fail to benefit colorectal cancer (CRC) patients. Relevant functional assays aimed at studying these failures and the efficacy of cancer immunotherapy in human are scarce. 3D tumor cultures, called tumor organoids or spheroids, represent interesting models to study cancer treatments and could help to challenge these issues. Methods: We analyzed heterotypic cocultures of human colon tumor-derived spheroids with immune cells to assess the infiltration, activation and function of T and NK cells toward human colorectal tumors in vitro. Results: We showed that allogeneic T and NK cells rapidly infiltrated cell line-derived spheroids, inducing immune-mediated tumor cell apoptosis and spheroid destruction. NKG2D, a key activator of cytotoxic responses, was engaged on infiltrating cells. We thus assessed the therapeutic potential of an antibody targeting the specific ligands of NKG2D, MICA and MICB, in this system. Anti-MICA/B enhanced immune-dependent destruction of tumor spheroid by driving an increased NK cells infiltration and activation. Interestingly, tumor cells reacted to immune infiltration by upregulating HLA-E, ligand of the inhibitory receptor NKG2A expressed by CD8 and NK cells. NKG2A was increased after anti-MICA/B treatment and, accordingly, combination of anti-MICA/B and anti-NKG2A was synergistic. These observations were ultimately confirmed in a clinical relevant model of coculture between CRC patients-derived spheroids and autologous tumor-infiltrating lymphocytes. Conclusions: Altogether, we show that tumor spheroids represent a relevant tool to study tumor-lymphocyte interactions on human tissues and revealed the antitumor potential of immunomodulatory antibodies targeting MICA/B and NKG2A. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
47. Phenotypic analysis of T cells infiltrating colon cancers: Correlations with oncogenetic status.
- Author
-
Chirica, Mircea, Le Bourhis, Lionel, Lehmann-Che, Jacqueline, Chardiny, Victor, Bouhidel, Fatiha, Foulboeuf, Laure, Gornet, Jean Marc, Lourenco, Nelson, Dulphy, Nicolas, Toubert, Antoine, and Allez, Matthieu
- Subjects
- *
COLON cancer , *T cells , *CELLULAR signal transduction , *CELL-mediated cytotoxicity , *CARCINOGENESIS - Abstract
Colorectal cancers (CRC) develop in the face of an important immune system associated with the intestinal mucosal tissue. The immune response against the tumor has been proposed to affect the prognosis of patients undergoing treatment for CRC. In this study T cells infiltrating the tumor were compared with T cells populating the unaffected neighboring mucosal tissue and cells from the peripheral blood. We observed that T cells from the tumor harbor an activated phenotype, with engagement of the NKG2D pathway in CD8 T cells. We show that mucosal and tumor-infiltrating T cells are enriched in NKG2D CD4 T cells, which exhibit cytotoxic functions. Finally, T cell populations in the tumor were modified according to its oncogenetic status, with higher percentages of CD8 T cells isolated from patients with microsatellite instable tumor status. [ABSTRACT FROM PUBLISHER]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.